Rationale, design and organisation of an efficacy and safety study of oxypurinol added to standard therapy in patients with NYHA class III – IV congestive heart failure

By Freudenberger Ronald S   Schwarz Jr Richard P   Brown Joanne   Moore Alan   Mann Douglas   Givertz Michael M   Colucci Wilson S   Hare Joshua M  

Expert Opinion on Investigational Drugs, Vol. 13, Iss. 11, 2004-11 ,pp. : 1509-1516

Informa Healthcare

Access to resources Recommend Favorite

Use and Risk Management of Carvedilol for the Treatment of Heart Failure in the Community in England: Results from a Modified Prescription-Event Monitoring Study

By Aurich-Barrera Beate   Wilton Lynda V.   Shakir Saad A.W.  

Drug Safety, Vol. 32, Iss. 1, 2009-01 ,pp. : 43-54

Adis International

Access to resources Recommend Favorite

Increasing Awareness and Perception of Heart Failure in Europe and Improving Care—Rationale and Design of the SHAPE Study

By Remme Willem   Boccanelli Alessandro   Cline Charles   Cohen-Solal Alain   Dietz Rainer   Hobbs Richard   Keukelaar Karen   Sendon Jose   Macarie Cezar   McMurray John   Rauch Bernhard   Ruzyllo Witold   Zannad Faiez  

Cardiovascular Drugs and Therapy, Vol. 18, Iss. 2, 2004-03 ,pp. : 153-159

Springer Publishing Company

Access to resources Recommend Favorite

Pilot study shows carvedilol promising in paediatric heart failure

By  

Inpharma, Vol. 1, Iss. 1290, 2001-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Carvedilol in the treatment of chronic heart failure

By Moe G.  

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 5, 2001-05 ,pp. : 831-843

Informa Healthcare

Access to resources Recommend Favorite